Baylor College of Medicine

Study on lonafarnib and ritonavir (H-45281)

Description

Content

Eiger eig-lnf-011 is a phase 3, matrix design, partially double-blind, randomized study of the efficacy and safety of 50 mg lonafarnib/ 100 mg ritonavir bid with and without 180 mcg peg ifn-alfa-2a for 48 weeks compared with peg ifn-alfa-2a monotherapy and placebo treatment in patients chronically infected with hepatitis delta virus being maintained on anti-hbv nucleos(t)ide therapy (d-livr).

Contact

Jana Lee

Phone 1: 713–798–1037

IRB: H-45281

Status:

Active

Created:

Back to topback-to-top